HOME >> MEDICINE >> NEWS
Novartis MS drug shows promising results

Basel, October 1, 2005 Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing multiple sclerosis (MS).

The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualized relapse rate of more than 50% during the first six months of the study compared to placebo maintained this low relapse rate during the subsequent six-month extension.

In patients who switched from placebo to either the 1.25 mg or 5 mg dosing of FTY720 after six months, the annualized relapse rate was reduced by at least 70% during the second six-month study phase compared to the first six months on placebo.

More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose (1.25 mg or 5 mg).

"We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the six-month placebo-controlled phase of the study," said chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland, "We hope that the magnitude of benefits shown in Phase II will be confirmed in the larger scale Phase III study program expected to be launched soon." Based on the positive Phase II study results, Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.

Over two million people worldwide are estimated to suffer from multiple sclerosis, which is the leading cause of neurological disability in young adults. MS is the most common ch
'"/>

Contact: Eva Reynolds
eva@reynoldsmackenzie.com
44-207-031-4361
Reynolds-MacKenzie
1-Oct-2005


Page: 1 2 3

Related medicine news :

1. BIDMC investigator receives Novartis Award in Diabetes
2. American Urological Association honors Novartis Pharmaceuticals with annual health science award
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Most seniors now have drug coverage, U-M study shows
5. Wireless technology shows promise in diagnosing pediatric intestinal disease
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Method shows promise for early detection of pancreatic cancer
8. Organic farming can feed the world, U-M study shows
9. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
10. Borderline personality disorder shows improvements with intensive psychotherapy
11. New drug shows promise in treatment of advanced thyroid cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... ... October 08, 2019 , ... Cognosante has ... Department of Veterans Affairs Community Care Referrals and Authorizations program. The new task ... Health Share Referral Manager (HSRM), an enterprise-wide system used by community care staff ...
(Date:10/8/2019)... COLLEGE PARK, Md. (PRWEB) , ... October 08, ... ... to observe fungal infection progression in live samples, Meiqing Shi, associate professor with ... in the field. In his latest paper published in Nature Communications, Shi and ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Over the past ... as a standout in the sports restaurant category by providing a higher-quality product and ... new fall menu as well as a "RAISE A MUG FOR THE CAUSE" campaign ...
(Date:10/8/2019)... ... 08, 2019 , ... METAvivor Research and Support Inc., a non-profit organization dedicated ... Stage IV Stampede campaign. The campaign will commence with two days of action and ... advocacy boot camp, a march, a Die-In (hosted by partner MET-UP), and visits with ...
(Date:10/8/2019)... FAYETTEVILLE, Ark. (PRWEB) , ... October 08, 2019 ... ... Hub has selected CardioWise, Inc. a Digital Health Awards 1st Round ... of UCSF Digital Health Awards was to select companies that promote faster, better, ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... Conn. (PRWEB) , ... October 19, 2019 , ... Hospital ... of 2019, according to new acquisition data from HealthCareMandA.com. The most recent quarter was ... Dollar volume was up sharply compared with the second quarter, totaling nearly $5.0 billion, ...
(Date:10/17/2019)... ... October 17, 2019 , ... Women’s concern in the wake of the ... implants is the subject of a September 24 article on CBS Miami. ... the Allergan recall has revived a number of issues, including a possible link between ...
(Date:10/15/2019)... ... October 14, 2019 , ... ... linearity and calibration verification kit, for Roche cobas® analyzers, Order No. 507ro. ... B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared using ...
Breaking Medicine Technology:
Cached News: